More on CAMP
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.90 |
|
|||
| Open | $3.87 | ||||
| 52 Wk High | $21.34 | ||||
| 52 Wk Low | $12.13 | ||||
| Day High | $4.01 | ||||
| Day Low | $3.78 | ||||
| P/E | 2.98 | ||||
| EPS | $1.33 | ||||
| Volume | 137,898 | ||||
- Camp4 Therapeutics gets EU approval for SYNGAP1 disorder trial
- CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
- Raymond James Starts CAMP4 Therapeutics Corp (CAMP) at Strong Buy
- Needham Starts CAMP4 Therapeutics Corp (CAMP) at Buy
- CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
- Oppenheimer Starts CAMP4 Therapeutics Corp (CAMP) at Outperform
- CAMP4 Therapeutics (CAMP) Reiterated at Overweight by Cantor Fitzgerald After Analyst Day
- CAMP4 Therapeutics Corp (CAMP) PT Lowered to $6 at Chardan
- Camp4 Therapeutics gets UK approval for SYNGAP1 drug trial
- CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Entities mentioned with CAMP
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- After-Hours Movers | View Related Stories »
- JPMorgan | View Related Stories »
- Canaccord Genuity | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
